Prof Allen Yeoh

Designations:

Head & Senior Consultant, Division of Paediatric Haematology and Oncology, Department of Paediatrics, Khoo Teck Puat - National University Children's Medical Institute, National University Hospital
Head & Senior Consultant, Division of Paediatric Haematology and Oncology, National University Cancer Institute, Singapore
Professor, Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore
Viva-Goh Foundation Professor in Paediatric Oncology, Yong Loo Lin School of Medicine, National University of Singapore

Qualifications:

MBBS (S'pore), MMed (Paeds) (S'pore)

Specialties/Sub-specialties:

Paediatric Haematology & Oncology, Paediatric Medicine

Clinical Disciplines/Programmes:

Paediatric Blood & Marrow Transplantation (BMT) Programme, Paediatrics, Paediatrics – Children’s Emergency

Special Interests:

Pharmacogenomics in childhood leukemias, treatment-related toxicities in childhood leukemias

Make an Appointment

Contact Us:

Find Out More:

Make an Appointment

Biosketch

Professor Allen Yeoh is the Head and Senior Consultant in the Division of Paediatric Haematology and Oncology in NCIS and NUH, as well as the VIVA-Goh Foundation Professor in Paediatric Oncology in Yong Loo Lin School of Medicine, NUS. He was trained in NUS and NUH and was a Clinical Fellow in St Jude Children's Research Hospital from 1999 to 2001.

Prof Yeoh's interest is in childhood leukaemia. He is currently the principal investigator of the multi-centre Malaysia-Singapore ALL and AML trials, competitively funded by NMRC. The Malaysia-Singapore trials have been highly successful with >80% and >60% projected cure respectively. He is the first Singaporean doctor to receive the American Society of Haematology Merit Award for his pioneering work in gene expression profiling in leukaemia and it was one of the highest cited articles in this field in 2003.

Prof Yeoh's focus is on translational clinical research in childhood acute lymphoblastic leukaemia (ALL). Specifically, he leads the VIVA-NUS Centre for Translational Research in Acute Leukaemia (CenTRAL) which provides actionable biomarkers to help guide treatment of ALL. These biomarkers include minimal residual disease quantitation and RNA-Seq. Together with Prof Dario Campana from NUSMed, Prof Yeoh leads the chimeric-antigen receptor-T (CAR-T) cells programme in NUHS.

Grants
As Principle Investigator:

NMRC CSA (SI): Feb 2019 - Aug 2024. Ma-Spore ALL-Seq 2020: RNA-Seq and IgH/TCR-Seq to improve risk assignment in childhood, adolescent and young adult ALL.
NMRC Centre Grant (CGAug16M005). Core 2. 2017 – 2021.
Clinical Pharmacology and Biomarkers Core -Childhood Malignancies

Awards

NMRC-BMRC Clinician Scientist Award from 2005 to date

Journals & Publications

Lazaro AM, Xiao Y, Masaberg C, Hwang WY, Yeoh AE, Weiyan Y, Ng J, Hurley CK, Posch PE. Novel HLA class I and II alleles identified during routine registry typing. Tissue Antigens,2011 Jul 5
Jiang N, Kham SK, Koh GS, Suang Lim JY, Ariffin H, Chew FT, Yeoh AE. Identification of prognostic protein biomarkers in childhood acute lymphoblastic leukemia (ALL). J Proteomics. 2011 May 16;74(6):843-57. Epub 2011 Mar 21.
Chan, J.Y-S., Ugrasena, D.G., Lum, D.W-K., Lu, Y. and Yeoh, A.E-J. Xenobiotic and folate pathway gene polymorphisms and risk of childhood acute lymphoblastic leukaemia in Javanese children. Hematological Oncology, 2010 Sep 7
Leong SM, Tan BX, Bte Ahmad B, Yan T, Chee LY, Koh LP, Yeoh AE, Koay ES, Mok YK, Lim TM. Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition. Blood. 2010 Oct 28:116(17):3286-96.
Kham SK, Soh CK, Aw DC, Yeoh AE. TPMT*26 (208F-->L), a novel mutation detected in a Chinese. Br J Clin Pharmacol. 2009 Jul;68(1):120-3.
Lazaro AM, Hwang WY, Yeoh AE, Ng J, Posch PE. Characterization of new HLA-B and -DRB1 alleles from Singapore. Tissue Antigens 2009 Jan;73(1):75-6.
Kham SK, Soh CK, Liu TC, Chan YH, Ariffin H, Tan PL, Yeoh AE. Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol 2008 Apr;64(4):373-9.
Ariffin H, Chen SP, Kwok CS, Quah TC, Lin HP, Yeoh AE. Ethnic differences in the frequency of subtypes of childhood acute lymphoblastic leukemia; results of the Malaysia-Singapore Leukemia Study Group. J Pediatr Hematol Oncol.2007 Jan;29(1):27-31
Tan RM, Quah TC, Aung L, Liang S, Kirk RC, Yeoh AE. Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol. Pediatr Blood Cancer, 2007 Mar, 48(3): 262-7
Kwok CS, Kham SK, Ariffin H, Lin HP, Quah TC, Yeoh AE. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer, 2006 Sep:47(3):299-304

Professional Memberships

International member, American Society of Hematology (ASH)
Director, Singapore Cord Blood Bank Limited (SCBB)
Member, Editorial Board for Pediatric Blood & Cancer
Director, St Jude-Viva Children Cancer Programme
Paediatric Oncology Group of Singapore
Member, Training and Education Fund, National University Cancer Institute, Singapore (NCIS)
Viva Children's Cancer Program Director, Viva Foundation
Scientific Chairman, St Jude Viva Forum
Member, Medical Advisory Board, Viva Foundation for Children with Cancer
Symposium Chairs, SARS, Cancer, Paediatric and Chairman's Symposia
Member, Medical Advisory Board, Children's Cancer Foundation

2024/08/16

Doctor Details